Resverlogix (FRA:RFS) YoY EPS Growth: 50.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RFS Resverlogix Corp FRA:RFS
17 GF Score
Price €0.06
! 5 Warning Signs
View Full Analysis

What is Resverlogix YoY EPS Growth?

Resverlogix FRA:RFS +3.57% 17 YoY EPS Growth is 50.00% as of Mar. 2026. GuruFocus rates FRA:RFS with a GF Score™ of 17/100. The stock has 5 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Resverlogix's YoY EPS Growth for the quarter that ended in Mar. 2026 was 50.00%.

Resverlogix's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was €-0.01.

Resverlogix YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Resverlogix's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resverlogix YoY EPS Growth Chart

Resverlogix Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -117.91 89.89 -511.11 47.27 10.34

Resverlogix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 52.63 100.00 0.00 50.00
FRA:RFS
17GF Score
Resverlogix Corp FRA:RFS
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Resverlogix YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Resverlogix's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-0.026--0.029)/ | -0.029 |
=10.34 %

Resverlogix's YoY EPS Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EPS Growth (Q: Mar. 2026 )
=(Earnings per Share (Diluted) (Q: Mar. 2026 )-Earnings per Share (Diluted) (Q: Mar. 2025 )) / | Earnings per Share (Diluted) (Q: Mar. 2025 )) |
=(-0.009--0.018)/ | -0.018 |
=50.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 50.00% mean?
Resverlogix (FRA:RFS) has a YoY EPS Growth of 50.00% as of Mar. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Resverlogix and its competitors.
Is Resverlogix's YoY EPS Growth too high?
Resverlogix's current YoY EPS Growth is 50.00%. Overall, Resverlogix has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Resverlogix's YoY EPS Growth compare to VRTX and REGN?
Resverlogix's YoY EPS Growth of 50.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Resverlogix and its competitors. Resverlogix's current YoY EPS Growth is 50.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resverlogix stock overvalued right now?
Resverlogix (FRA:RFS) has a current YoY EPS Growth of 50.00%. The current YoY EPS Growth is 50.00%. Resverlogix's overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Resverlogix (FRA:RFS), the current YoY EPS Growth is 50.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Resverlogix Business Description

Other Exchanges RVXCF:USARVX:Canada
Address 4820 Richard Road SW, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
17GF Score

Get the complete analysis for FRA:RFS

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.06
Price